110 related articles for article (PubMed ID: 17047370)
1. Modulators and inhibitors of gamma- and beta-secretases.
Schmidt B; Baumann S; Narlawar R; Braun HA; Larbig G
Neurodegener Dis; 2006; 3(4-5):290-7. PubMed ID: 17047370
[TBL] [Abstract][Full Text] [Related]
2. Aspartic proteases involved in Alzheimer's disease.
Schmidt B
Chembiochem; 2003 May; 4(5):366-78. PubMed ID: 12740808
[TBL] [Abstract][Full Text] [Related]
3. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure.
Hahn S; Brüning T; Ness J; Czirr E; Baches S; Gijsen H; Korth C; Pietrzik CU; Bulic B; Weggen S
J Neurochem; 2011 Feb; 116(3):385-95. PubMed ID: 21091478
[TBL] [Abstract][Full Text] [Related]
4. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
Harrison T; Churcher I; Beher D
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
[TBL] [Abstract][Full Text] [Related]
5. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.
Rajendran L; Schneider A; Schlechtingen G; Weidlich S; Ries J; Braxmeier T; Schwille P; Schulz JB; Schroeder C; Simons M; Jennings G; Knölker HJ; Simons K
Science; 2008 Apr; 320(5875):520-3. PubMed ID: 18436784
[TBL] [Abstract][Full Text] [Related]
6. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
7. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Pollack SJ; Lewis H
Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
[TBL] [Abstract][Full Text] [Related]
8. Role of amyloid precursor protein, amyloid-beta and gamma-secretase in cholesterol maintenance.
Hartmann T
Neurodegener Dis; 2006; 3(4-5):305-11. PubMed ID: 17047372
[TBL] [Abstract][Full Text] [Related]
9. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond.
De Strooper B; Chávez Gutiérrez L
Annu Rev Pharmacol Toxicol; 2015; 55():419-37. PubMed ID: 25292430
[TBL] [Abstract][Full Text] [Related]
10. Gamma-secretase: a complex target for Alzheimer's disease.
Lundkvist J; Näslund J
Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
[TBL] [Abstract][Full Text] [Related]
11. Designed helical peptides inhibit an intramembrane protease.
Das C; Berezovska O; Diehl TS; Genet C; Buldyrev I; Tsai JY; Hyman BT; Wolfe MS
J Am Chem Soc; 2003 Oct; 125(39):11794-5. PubMed ID: 14505382
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of gamma-secretase by the CK1 inhibitor IC261 does not depend on CK1delta.
Höttecke N; Liebeck M; Baumann K; Schubenel R; Winkler E; Steiner H; Schmidt B
Bioorg Med Chem Lett; 2010 May; 20(9):2958-63. PubMed ID: 20350806
[TBL] [Abstract][Full Text] [Related]
13. Novel γ-secretase modulators: a review of patents from 2008 to 2010.
Pettersson M; Kauffman GW; am Ende CW; Patel NC; Stiff C; Tran TP; Johnson DS
Expert Opin Ther Pat; 2011 Feb; 21(2):205-26. PubMed ID: 21231889
[TBL] [Abstract][Full Text] [Related]
14. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
Silvestri R
Med Res Rev; 2009 Mar; 29(2):295-338. PubMed ID: 18651582
[TBL] [Abstract][Full Text] [Related]
15. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.
Esler WP; Kimberly WT; Ostaszewski BL; Diehl TS; Moore CL; Tsai JY; Rahmati T; Xia W; Selkoe DJ; Wolfe MS
Nat Cell Biol; 2000 Jul; 2(7):428-34. PubMed ID: 10878808
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
17. Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.
Lewis HD; Pérez Revuelta BI; Nadin A; Neduvelil JG; Harrison T; Pollack SJ; Shearman MS
Biochemistry; 2003 Jun; 42(24):7580-6. PubMed ID: 12809514
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors and modulators of beta- and gamma-secretase.
Schmidt B; Baumann S; Braun HA; Larbig G
Curr Top Med Chem; 2006; 6(4):377-92. PubMed ID: 16611149
[TBL] [Abstract][Full Text] [Related]
19. Control of amyloid-beta-peptide generation by subcellular trafficking of the beta-amyloid precursor protein and beta-secretase.
Walter J
Neurodegener Dis; 2006; 3(4-5):247-54. PubMed ID: 17047364
[TBL] [Abstract][Full Text] [Related]
20. A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β-secretase inhibitors.
Gay M; Evrard C; Descamps F; Carato P; Renault N; Coevoet M; Eddarkaoui S; Baud C; Larchanché PE; Buée L; El Bakali J; Vingtdeux V; Sergeant N; Melnyk P
Eur J Med Chem; 2018 Nov; 159():104-125. PubMed ID: 30268822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
